 A new therapeutic vaccine (Nexvax2) for celiac disease is currently being developed and could potentially prove efficacious to individuals with dermatitis herpetiformis who have the HLA-DQ2 haplotype.The vaccine contains three fragments, or epitopes, commonly found on gluten that are thought to be responsible for the pro-inflammatory response in patients with celiac disease.By introducing these epitopes to the immune system, the vaccine aims to induce immune tolerance to gluten via introduction of progressively higher doses of the vaccine over time.